ISRCTN11898283 https://doi.org/10.1186/ISRCTN11898283

Using virtual reality (VR) to reduce fear of heights

Submission date	Recruitment status	[X] Prospectively registered
01/10/2017	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
04/10/2017	Completed	[X] Results
Last Edited	**Condition category**	[ ] Individual participant data
17/07/2018	Mental and Behavioural Disorders	

Plain English summary of protocol

Background and study aims
Cognitive behavioural therapy (CBT) or exposure therapy delivered by virtual reality (VR) has been shown in a number of studies to be a safe and effective way of reducing anxieties. A state-of-the-art VR cognitive behavioural treatment has been developed for fear of heights that is automated, engaging, and deliverable via the latest consumer equipment. The aim of this study is to test whether the VR treatment reduces fear of heights at the end of treatment, and whether the treatment gains are maintained at follow-up.

Who can participate?
People aged over 18 who report a fear of heights

What does the study involve?
Participants are randomly allocated to receive the VR treatment or no treatment. The VR treatment is provided in six sessions over about a fortnight. Fear of heights is assessed using questionnaires at the start of the study, after treatment, and two weeks after the end of treatment.

What are the possible benefits and risks of participating?
The potential benefits for participants are a reduction in their fear of heights. There are unlikely to be any risks in participating although sometimes people get short-term motion sickness with VR (though this has not been found to occur with this VR set-up).

Where is the study run from?
University of Oxford (UK)

When is the study starting and how long is it expected to run for?
May 2017 to May 2018

Who is funding the study?
Oxford VR/Nowican (UK)

Who is the main contact?
1. Polly Haselton
phaselton@oxfordvr.org
2. Prof. Daniel Freeman

Contact information

Type(s)
Public

Contact name
Ms Polly Haselton

Contact details
King Charles House
Park End Street
Oxford
United Kingdom
OX1 1JD
+44 (0)7388 872 383
phaselton@oxfordvr.org

Type(s)
Scientific

Contact name
Prof Daniel Freeman

Contact details
Department of Psychiatry
Warneford Hospital
University of Oxford
Oxford
United Kingdom
OX3 7JX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
R52909/RE001

Study information

Scientific Title
Using virtual reality (VR) to reduce fear of heights: a parallel-group, randomised controlled trial of a virtual reality cognitive behavioural therapy based programme for fear of heights

Study objectives
The primary hypothesis is that the VR treatment, compared to a non-intervention control group, will reduce fear of heights at the end of treatment.
The secondary hypothesis is that the treatment gains will be maintained at follow-up.

Ethics approval required
Old ethics approval format

Ethics approval(s)
University of Oxford Medical Sciences Inter-Divisional Research Ethics Committee, ref: R52909 /RE001

Study design
Parallel-group randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Community

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied
Fear of heights

Interventions
Participants will be randomly allocated, stratified by fear of height severity and using randomised permuted blocks, to VR treatment or control (no treatment). The VR cognitive behavioural treatment for fear of heights is automated and is delivered in six sessions, typically lasting 20-30 minutes, over approximately a fortnight.

The outcomes are self-report assessments of fear of heights, with neither participant nor researcher blind to randomisation allocation, conducted at 0, 2 (post-treatment), and 4 weeks (a fortnight after treatment ends).

Updated 18/10/2017:
The outcomes are self-report assessments of fear of heights, with the researcher administrating the assessments blind to randomisation allocation, conducted at 0, 2 (post-treatment), and 4 weeks (a fortnight after treatment ends).

Intervention Type
Behavioural

Primary outcome measure
Fear of heights, assessed using the Heights Interpretation Questionnaire (Steinman and Teachman, 2011) at 0, 2 (post-treatment), and 4 weeks (a fortnight after treatment ends)

Secondary outcome measures
Fear of heights, assessed using the Acrophobia Questionnaire (AQ) (Cohen, 1977); Phobia Avoidance item 3 (IAPT, 2008) at 0, 2 (post-treatment), and 4 weeks (a fortnight after treatment ends)

Overall study start date
01/05/2017

Completion date
01/05/2018

Eligibility

Key inclusion criteria
1. Adults (18+ years old)
2. Fear of heights (Heights Interpretation Questionnaire score of 30 or greater)

Participant type(s)
Healthy volunteer

Age group
Adult

Lower age limit
18 Years

Sex
Both

Target number of participants
100

Key exclusion criteria
1. Current psychological treatment for fear of heights
2. Unable to travel to research appointments
3. Photosensitive epilepsy
4. Lack of stereoscopic vision or balance problems

Date of first enrolment
01/11/2017

Date of final enrolment
27/02/2018

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Oxford VR/Nowican
King Charles House
Park End Street
Oxford
United Kingdom
OX1 1JD

Sponsor information

Organisation
University of Oxford

Sponsor details
Clinical Trials Research Governance
Joint Research Office
Block 60
Churchill Hospital
Oxford
England
United Kingdom
OX3 7LE

Sponsor type
University/education

ROR
https://ror.org/052gg0110

Funder(s)

Funder type
Industry

Funder Name
Oxford VR/Nowican

Results and Publications

Publication and dissemination plan
Submission of a paper to a peer-reviewed psychiatric/mental health journal in May 2018.

Intention to publish date
01/05/2018

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are not expected to be made available. The data will be held by Oxford VR.

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2018		Yes	No